A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

Healthy Volunteers Diabetes Mellitus, Type 2 Clinical Trial

Official title: A Trial to Compare the Injection Site Pain Experience of 0.25 mg Semaglutide B and Semaglutide D Administered sc

Status Completed

Clinical Trial Summary

This study in healthy men and women looks at the injection site experience of the DV3396 pen to that of the PDS290 pens when both pens are used to deliver 0.25 mg semaglutide subcutaneously (s.c., under the skin). Participants will receive 2 single doses of semaglutide 0.25 mg on 1 day. The 2 injections will be given at least 30 minutes apart, one in each side of the stomach. Participants will be in the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5 weeks after the injections were given.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Healthy Volunteers Diabetes Mellitus, Type 2
• Healthy Volunteers Obesity
• Healthy Volunteers Overweight
• Obesity
• Overweight

• NCT number: NCT04143945
• Study type: Interventional
• Source: Novo Nordisk A/S
• Status: Completed
• Phase: Phase 2
• Start date: October 28, 2019
• Completion date: January 4, 2020